Reshaping the tumor microenvironment of cold soft-tissue sarcomas with anti-angiogenics: a phase 2 trial of regorafenib combined with avelumab
{{output}}
The majority of sarcomas are under the influence of a tumor microenvironment that dampens immune activity, resulting in resistance to monoclonal antibodies targeting immune checkpoints and reduced clinical effectiveness. Preclinical studies indicate that targe... ...
